Sanofi races to the AI forefront in Big Pharma; Plus, Medable's big promises for clinical trials

This episode of DeviceTalks AI offers a comprehensive look at the ways AI is poised to upend the pharmaceutical industry. It features an in-depth keynote interview with Helen Merianos, Head of Sanofi's R&D Portfolio Strategy, who provides an inside look into Sanofi's commitment to go "all-in" on AI and data science. Merianos discusses the use of Sanofi's proprietary plai app – an AI-enabled smartphone app that draws from over a billion data points – and its role in establishing a data-driven culture across the company. Additionally, the episode features Michelle Longmire, MD, Co-Founder and CEO of Medable, who discusses the use of generative AI in automating and accelerating clinical trial technology deployment timelines. These applications could cut some timelines in half. Longmire envisions AI's potential to drastically accelerate a development process. “Say there's 10,000 uncured or poorly suboptimally treated human diseases.” At the current pace of drug development, it might take about 200 years to create treatments for those conditions. “Imagine if we could 10x that,” Longmire says. Join us for the next episode of DeviceTalks AI, where we sit down with Ha Hong, PhD, Chief Artificial Intelligence Officer, Endoscopy at Medtronic. Thank you to our sponsors Catalyze Healthcare and SmartTRAK Business Intelligence, for providing invaluable support. catalyzehealthcare.com smarttrak.com Tune in and subscribe to DeviceTalks AI on all major podcast channels and follow youtube.com/@DeviceTalks to ensure you never miss an episode. WATCH, LISTEN, and READ: https://www.drugdiscoverytrends.com/when-will-drug-development-have-its-chatgpt-moment-inside-ambitious-ai-initiatives-at-sanofi-and-medable/ Thank you for supporting DeviceTalks AI!

There are no comments yet.

Please log in to write the first comment.